Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Duarte, California 91010


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining topotecan and cytarabine given with amifostine in treating patients who have myelodysplastic syndrome.

Study summary:

OBJECTIVES: - Determine the toxic effects of amifostine, topotecan, and cytarabine in patients with poor risk myelodysplastic syndrome. - Determine the hematologic response rate, cytogenetic response rate, and the rate of polyclonal hematopoiesis following this treatment regimen. - Determine the duration of response and time to disease progression following this treatment regimen in these patients. OUTLINE: Patients receive topotecan by continuous IV over 24 hours plus cytarabine IV over 2 hours, on days 1-5. Patients receive amifostine IV over 15 minutes every other day for a maximum of 60 days. Patients may receive a second course of the same regimen 8 weeks after the first. Patients are followed at least monthly for 2 years, then every 3-6 months until death. PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study within 1 to 1.5 years.


DISEASE CHARACTERISTICS: - Histologically confirmed poor risk myelodysplastic syndrome, including at least one of the following: - Bilineage cytopenia - Unfavorable cytogenetic abnormalities - Refractory anemia with excess blasts and/or refractory anemia with excess blast in transformation (greater than 5% blast) - At least 0.5 on the International Prognostic Score System - No chronic myelomonocytic leukemia - No hypocellular myelodysplastic syndrome (marrow cellularity less than 30%) PATIENT CHARACTERISTICS: Age: - 16 and over Performance status: - ECOG 0-1 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count less than 1,500/mm3 - Platelet count less than 100,000/mm3 - Hemoglobin less than 10 g/dL Hepatic: - ALT less than 5 times upper limit of normal Renal: - Creatinine no greater than 1.4 mg/dL Cardiovascular: - No congestive heart failure Other: - Not pregnant or nursing - Fertile patients must use effective contraception - Must have right atrial catheter inserted PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior blood or bone marrow transplantations Chemotherapy: - No prior acute myeloid leukemia chemotherapy (except hydroxyurea or low dose cytarabine) - No prior topotecan - No prior amifostine Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified Other: - At least 24 hours since prior antihypertensive medication prior to amifostine



Primary Contact:

Study Chair
Henry C. Fung, MD, FRCPE
Beckman Research Institute

Backup Contact:


Location Contact:

Duarte, California 91010
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.